{
  "source": "PA-Notification-Omvoh.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1425-3\nProgram Prior Authorization/Notification\nMedication * Omvoh™ (mirikizumab-mrkz)\n*This program applies to the subcutaneous formulation of Omvoh.\nP&T Approval Date 1/2024, 1/2025, 3/2025\nEffective Date 5/1/2025\n1. Background:\nOmvoh (mirikizumab-mrkz) is an interleukin-23 antagonist indicated for the treatment of\nmoderately to severely active ulcerative colitis in adults and moderately to severely active\nCrohn's disease in adults.\n2. Coverage Criteriaa:\nA. Ulcerative Colitis (UC)\n1. Initial Authorization for Maintenance Dosing\na. Omvoh will be approved based on both of the following criteria:\n(1) Diagnosis of moderately to severely active ulcerative colitis\n-AND-\n(2) Patient is not receiving Omvoh in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept),\nEntyvio (vedolizumab), Olumiant (baricitinib), Orencia (abatacept), Rinvoq\n(upadacitinib), Simponi (golimumab), Skyrizi (risankizumab), ustekinumab,\nTremfya (guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Zeposia (ozanimod)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Omvoh will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Omvoh therapy\n-AND-\n(2) Patient is not receiving Omvoh in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Entyvio (vedolizumab), Olumiant (baricitinib), Orencia\n(abatacept), Rinvoq (upadacitinib), Simponi (golimumab), Skyrizi\n(risankizumab), ustekinumab, Tremfya (guselkumab), Xeljanz/Xeljanz XR\n(tofacitinib), Zeposia (ozanimod)]\n© 2025 UnitedHealthcare Services, Inc.\n1\nAuthorization will be issued for 12 months.\nB. Crohn’s Disease (CD)\n1. Initial Authorization for Maintenance Dosing\na. Omvoh will be approved based on both of the following criteria:\n(1) Diagnosis of moderately to severely active Crohn’s disease\n-AND-\n(2)",
    "Disease (CD)\n1. Initial Authorization for Maintenance Dosing\na. Omvoh will be approved based on both of the following criteria:\n(1) Diagnosis of moderately to severely active Crohn’s disease\n-AND-\n(2) Patient is not receiving Omvoh in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq\n(upadacitinib), Simponi (golimumab), Skyrizi (risankizumab-rzaa),\nustekinumab, Xeljanz (tofacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Omvoh will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Omvoh therapy\n-AND-\n(2) Patient is not receiving Omvoh in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq\n(upadacitinib), Simponi (golimumab), Skyrizi (risankizumab-rzaa),\nustekinumab, Xeljanz (tofacitinib)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n• The intravenous infusion is typically covered under the medical benefit. Please refer to the\nUnitedHealthcare Drug Policy for Omvoh.\n© 2025 UnitedHealthcare Services, Inc.\n2\n4. Reference:\n1. Omvoh [package insert]. Indianapolis, IN: Eli Lilly and Company; January 2025.\nProgram Prior Authorization/Notification - Omvoh (mirikizumab-mrkz)\nChange Control\n1/2024 New program\n1/2025 Annual rev",
    ". Omvoh [package insert]. Indianapolis, IN: Eli Lilly and Company; January 2025.\nProgram Prior Authorization/Notification - Omvoh (mirikizumab-mrkz)\nChange Control\n1/2024 New program\n1/2025 Annual review with no change to clinical criteria. Updated examples\nwith no change to clinical intent. Updated reference.\n3/2025 Added coverage criteria for Crohn’s disease. Updated background and\nreference.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}